To achieve Vision 2030 of the Kingdom of Saudi Arabia and the role of King Saud University in leveraging its capabilities by investing in knowledge-based companies locally and globally through its investment arm Riyadh Valley Company; RVC announce its participation in round C of investment in the Swedish company Vironova. Vironova is a medical technology and software company with key capabilities in TEM for nanoparticle analysis. The company is an innovative player in the field of nanoparticle analysis and started as a service provider. Since 2014 Vironova focused on the supply of hardware and software for the nanoparticle analysis. “Its main product the MiniTEM”, says Dr. Khalid Alsaleh, CEO of RVC, “in combination with the Vironova Analyzer Software (VAS) provides proprietary image analysis for identifying and analyzing nano-sized particles in transmission electron microscopy (TEM) images at a low nominal acceleration. He also added: “This investment opportunity falls under one of RVC’s main focus industries in a step to enable RVC building a balanced local and global portfolio that achieves Kind Saud University’s goals and contributes to the enhancement of the economic competitiveness and development of the Kingdom of Saudi Arabia.
Riyadh Valley Company (RVC), King Saud University (KSU)’s investment vehicle, is a strategic investor, focused on leveraging the local capabilities, investing locally and globally in early-stage and growth businesses to create financial returns and strategic returns that will support the future of economic development of the Kingdom of Saudi Arabia.
